Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That … (NCT02464228) | Clinical Trial Compass
CompletedPhase 2
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
United States65 participantsStarted 2016-02-25
Plain-language summary
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL). Tipifarnib will be administered orally until disease progression.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Diagnosis of PTCL according to the most recent edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic or Lymphoid Tissues, as follows:
✓. Anaplastic large cell lymphoma (ALCL), ALK positive
✓. ALCL, ALK negative
✓. Angioimmunoblastic T-cell lymphoma (AITL)
✓. Enteropathy-associated T-cell lymphoma
✓. Extranodal natural killer (NK) T-cell lymphoma, nasal type
✓. Hepatosplenic T-cell lymphoma
✓. Peripheral T-cell lymphoma, not otherwise specified (NOS)
Exclusion criteria
✕. Diagnosis of any of the following:
✕. Precursor T-cell lymphoma or leukemia
✕. Adult T-cell lymphoma/leukemia (ATLL)
✕. T-cell prolymphocytic leukemia
✕. T-cell large granular lymphocytic leukemia
✕. Primary cutaneous type anaplastic large cell lymphoma